Article

Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancer

2020-05-07

Abstract excerpt

<h4>SUMMARY</h4> Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRC) but acquired resistance invariably evolves. Which mutational mechanisms enable resistance evolution and whether adaptive mutagenesis, a transient cetuximab-induced increase in mutagenesis, contributes in patients is unknown. We investigated this in exome sequencing data of 42 baseline and progr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8c84f6b6-f433-59ac-85aa-732f72f2c276
DOI: 10.1101/2020.05.07.082339

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancerDOI 10.1101/2020.05.07.082339Read

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.Semantic proximity Read

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.Semantic proximity Read

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Semantic proximity Read

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Semantic proximity Read

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read

Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancerSemantic proximity Read

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.Semantic proximity Read

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read